Ripretinib, sold under the brand name Qinlock, is a medication for the treatment of adults with advanced gastrointestinal stromal tumor (GIST), a type of tumor that originates in the gastrointestinal tract. It is taken by mouth. Ripretinib inhibits the activity of the kinases KIT and PDGFRA, which helps keep cancer cells from growing.
{{Infobox drug | image = Ripretinib skeletal.svg | image_class = skin-invert-image | width = | alt = | caption =
| pronounce = rip re' ti nib | tradename = Qinlock | Drugs.com = | MedlinePlus = a620035 | DailyMedID = Ripretinib | pregnancy_AU = D | pregnancy_AU_comment = | pregnancy_category= Use should be avoided | routes_of_administration = By mouth | class = | ATC_prefix = L01 | ATC_suffix = EX19 | ATC_supplemental =
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).